A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?
This article was originally published in PharmAsia News
MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago
You may also be interested in...
A workshop of senior executives deliberated on the next growth phase for Indian pharmaceutical companies and most came up with transformational ideas.
Analysts are divided on whether Sudhir Valia’s investments in Telenor’s new India joint venture may prove to be a backdoor way to indirectly channel funds from Sun Pharma.
Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business
MUMBAI - Could Lupin Ltd. be the next to sell off its India business to a multinational drug company? Sources report that Lupin is considering selling its India business for a deal valued at as much as $1 billion, and several market analysts in India say the question is not without merit